Computational Evaluation of PROTAC-Mediated Protein Degradation: Case Studies and Recent Developments 
Michael Drummond, Scientific Applications Manager, Chemical Computing Group
Multiparameter Optimization in Drug Discovery 
Istvan Enyedy, Principal Scientist, Biogen
An Iterative Scaffold-Hopping Strategy for The Design of Selective PI3K-δ Inhibitors 
Xavier Fradera, Associate Principal Scientist, Merck
Fragment Hits and Leads: More Than Meets the Eye 
Fabrizio Giordanetto, Head Medicinal Chemistry, D.E. Shaw Research
A Small-Molecule Inhibitor of C5 Complement Protein 
Keith Jendza, Scientific Technical Leader I, Novartis
Ligand-based Design of a Selective Antagonist of TRPA1 That Demonstrates Potent In Vivo Activity 
Laurie Schenkel, Associate Director, Ribon Therapeutics
Discovery of JAK1 Selective Kinase Inhibitor, AZD4205 
Qibin Su, Associate Principal Scientist, AstraZeneca
Discovery of Selective M4 Muscarinic Acetylcholine Receptor Agonists with Novel Carbamate Isosteres 
Joy Yang, Scientist, Pfizer
December 05, 2019
 
08:00-08:30
Welcome Refreshments / Registration Opens (Check-In and Badge Pick-Up)
08:30-10:00
Structure Based Drug Design and Docking
Structure Family Search / Protein-Ligand Interaction Fingerprints / MOE Project / Docking / Pharmacophore Modeling
10:00-10:30
Morning Break
10:30-12:00
De Novo Design and Library Generation
Scaffold Replacement / MedChem Transformations / Reaction-Guided Library Enumeration / R-Group Screening
12:00-13:00
Workshop Lunch
13:00-13:30
Registration (Check-In and Badge Pick-Up)
13:30-13:35
Opening Remarks
13:35-15:35
Scientific Presentations
15:35-16:05
Afternoon Break
16:05-18:05
Scientific Presentations
18:05-18:10
Closing Remarks
18:10-19:10
Social Reception